Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System

Samankaltaisia teoksia

• Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
  Tekijä: Raschi, Emanuel, et al.
  Julkaistu: (2020)
• Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
  Tekijä: Raschi, Emanuel, et al.
  Julkaistu: (2021)
• Chapter Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety
  Tekijä: Cosimo Antonazzo, Ippazio, et al.
  Julkaistu: (2019)
• Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
  Tekijä: Raschi, Emanuel, et al.
  Julkaistu: (2020)
• Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
  Tekijä: Gatti, Milo, et al.
  Julkaistu: (2021)